Should I act on the GlaxoSmithKline share price or buy AstraZeneca instead?

Our writer considers whether the GlaxoSmithKline share price could make it an attractive addition for his portfolio, compared to rival AstraZeneca.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Among leading UK pharma shares, both GlaxoSmithKline (LSE: GSK) and AstraZeneca (LSE: AZN) have been in the spotlight recently. Glaxo has been attracting attention for its plans to split into two parts, with its pharma business and consumer goods operation going separate ways. AstraZeneca’s visibility has been heightened by its vaccine. Both share prices have been moving up, but more slowly than the FTSE 100 index. The GlaxoSmithKline share price has added 9% over the past year, while AstraZeneca is up 12%, at the time of writing this article earlier today.

I’ve been investigating both of these FTSE 100 shares as potential additions to my portfolio. Here’s what I think.

Growth prospects

AstraZeneca has never been a very consistent performer when it comes to earnings. That reflects its pharma focus, where new drugs can sell very well but profits can fall away as patents expire. Currently it has a promising pipeline of drugs, which I think could help support growth in both revenues and profits in years to come. But pharma development costs are high for uncertain reward – that could weigh on future revenues and profits at AstraZeneca, as well as its rivals.

The growth outlook for Glaxo is less clear. Indeed one of the reasons some investors have agitated for change at the company is that they have been underwhelmed by its performance. On one hand, both revenues and profits have grown in recent years and that could continue. On the other, future sources of strong growth are not that obvious to me. However, splitting the company into two could help provide sharper focus in both the pharma and consumer goods businesses. So that could in itself act as a spur to growth.

Dividend yield

AstraZeneca offers a 2.2% dividend yield, and has not raised its dividend for years. At face value, Glaxo’s yield of 5.1% looks a lot more attractive. It also has not raised its dividend for years, though. Added to that, the company has guided investors to expect a lower total dividend once the company splits.

Even with the dividend cut, I reckon buying GlaxoSmithKline today could offer better dividend earnings potential to my portfolio than investing in AstraZeneca.

The GlaxoSmithKline share price valuation compared to AstraZeneca

AstraZeneca is trading on a price-to-earnings ratio of 52. In sharp contrast, Glaxo’s P/E ratio is just 13. In other words, the GlaxoSmithKline share price looks four times as cheap on this metric as AstraZeneca.

I don’t think that tells the full story, though. AstraZeneca earnings are forecast to grow sharply due to new products, which could make its prospective valuation more attractive. So the gap between the two valuations might not be quite as dramatic as it first looks.

Nonetheless, the GlaxoSmithKline share price looks a lot cheaper right now than its rival. It has a more attractive dividend yield, and I think that could be the case even if reduced after the split. While AstraZeneca’s pipeline is exciting, Glaxo has a solid enough portfolio of products and brands that I think it can also do well in future. Both companies face risks of unsuccessful drug development hurting profits. But when thinking about to what I could buy for my portfolio, I currently consider the GlaxoSmithKline share price to offer me better value than AstraZeneca.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Christopher Ruane has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Road 2025 to 2032 new year direction concept
Investing Articles

This under‑the‑radar FTSE 100 growth stock is also a secret dividend superstar!

Harvey Jones belatedly wakes up to a brilliant FTSE 100 growth stock that has an equally remarkable track record of…

Read more »

Business manager working at a pub doing the accountancy and some paperwork using a laptop computer
Investing Articles

Barratt Redrow share price plunges 9% on profits hit – time to consider buying?

Harvey Jones says FTSE 100 housebuilders continue to suffer with the Barratt Redrow share price slumping on a profit warning.…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Growth Shares

Why the next month could make or break the Lloyds share price

Jon Smith outlines two key events in coming weeks that could influence the Lloyds share price, leading him to make…

Read more »

This way, That way, The other way - pointing in different directions
Investing Articles

The B&M share price falls 13% despite improved Q1 sales. What should investors do?

Despite sales growing on a like-for-like basis, the B&M share price is falling yet again. So is the FTSE 250…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

Prediction: in 12 months, ultra‑high-yielding Phoenix shares could turn £10,000 into…

Harvey Jones has done nicely out of his Phoenix shares, as the FTSE 100 insurer gives him both growth and…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

This FTSE 100 passive income gem now has a forecast yield of a stunning 8.5%, so should I buy more?

This FTSE 100 dividend giant already has a very high yield, and is projected to go even higher in the…

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

3 key reasons why I think BP’s share price could soar following a 16% fall over the year…

BP’s share price has lost considerable ground over the course of the year, but I think there are three reasons…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

Building a second income with FTSE 100 dividend shares: my simple 3-step plan

Mark Hartley outlines a straightforward three-step approach to building a second income portfolio with well-established FTSE 100 dividend shares.

Read more »